Celgene’s New Revlimid® Lawsuits Shows Shifting Tactics From Earlier Natco Case
Celgene faces a new gang of generics moving in on its blockbuster Revlimid®. Over the past year, a number of generics have filed ANDAs against Revlimid®, including Dr. Reddy’s, Zydus, Cipla, and Lotus Pharmaceutical. Those ANDAs have triggered corresponding Hatch-Waxman lawsuits from Celgene. Among the asserted patents, most of them expire by 2022, with the exception of two polymorph patents that could extend Revlimid® monopoly until 2027. The lawsuits are in their early stages, but an upcoming Markman hearing in the case against Dr. Reddy’s is shaping up to be critical to whether Celgene can protect is Revlimid® monopoly past 2022. See our recent publication in IPWatchdog outlining the case in more detail.